AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Can-Fite Biopharma shares surge 18.15% after-hours as company announces strategic partnerships for Namodenoson at BioFIT 2025.
ByAinvest
Monday, Nov 24, 2025 5:43 pm ET1min read
Can-Fite BioPharma surged 18.15% in after-hours trading following the announcement of its participation in BioFIT 2025, where the company aims to advance a veterinary partnership for its Phase III anti-cancer drug, Namodenoson. The news highlighted Namodenoson’s potential in the veterinary oncology market, projected to reach $3.1 billion by 2030, and referenced a prior partnership with Vetbiolix that could generate $325 million in royalties. This strategic move underscores the company’s focus on expanding Namodenoson’s applications and securing collaborations with major animal health firms like Elanco and Zoetis. Despite underlying financial challenges, the bullish reaction reflects optimism around new partnership opportunities and the drug’s strong clinical profile, including its demonstrated safety and anti-tumor efficacy.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet